Division of Pediatric Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics, University of Pittsburgh, School of Medicine and UPMC Children's Hospital of Pittsburgh, Pittsburgh, PA, USA.
Department of Pharmacy, UPMC Children's Hospital of Pittsburgh, University of Pittsburgh School of Pharmacy, Pittsburgh, PA, USA.
Paediatr Drugs. 2022 Jul;24(4):365-376. doi: 10.1007/s40272-022-00512-3. Epub 2022 May 23.
Pediatric intestinal transplant serves as the only definitive treatment for children with irreversible intestinal failure. Successful intestinal transplant hinges upon appropriate management of immunosuppression. The indications for intestinal transplant have changed over time. Immunosuppression regimens can be divided into induction and maintenance phases along with treatment of acute rejection. Intestinal transplant induction now often includes antithymocyte globulin or basiliximab in addition to corticosteroids. Maintenance regimens continue to be dominated by tacrolimus, with additional agents used to either decrease goal tacrolimus levels to limit toxicity or as an adjunct in sensitized patients. Careful monitoring can help to limit serious complications, such as rejection, infection, and malignancy. Future work will aim to decrease variation in practice and identify methods to determine optimal immunosuppression for a particular patient. Furthermore, there is a need for non-invasive monitoring of the intestinal graft and functional assessments of immunosuppression.
儿科肠移植是治疗不可逆肠衰竭儿童的唯一根治方法。成功的肠移植取决于免疫抑制的适当管理。肠移植的适应证随着时间的推移而发生了变化。免疫抑制方案可分为诱导期和维持期,并可治疗急性排斥反应。现在,肠移植诱导通常包括抗胸腺细胞球蛋白或巴利昔单抗加皮质类固醇。维持方案仍以他克莫司为主,其他药物用于降低目标他克莫司水平以限制毒性,或作为致敏患者的辅助治疗。仔细监测有助于限制严重并发症,如排斥反应、感染和恶性肿瘤。未来的工作将旨在减少实践中的差异,并确定确定特定患者最佳免疫抑制的方法。此外,还需要对肠移植物进行非侵入性监测和对免疫抑制进行功能评估。